netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

Chapter Links...
 Details...
06.01  Drugs used in diabetes
06.01.01  Insulins
06.01.01.01  Short-acting insulins
Insulin Aspart  (NovoRapid®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Insulin Aspart (rapid acting) (Fiasp®)
View adult BNF View SPC online
Formulary
Amber 2

Insulins to be prescribed by brand name

Second-line fast acting insulin restricted to use where the first line fast acting insulin does not provide adequate post-prandial plasma glucose (PPG) control.

Approved in the following patient cohorts only:

  • Adult T1DM or cystic fibrosis related diabetes.
  • Pregnant women with diabetes (T1DM or T2DM) or gestational diabetes where post prandial control is of particular importance for foetal health.
  • Where a post-meal insulin injection would be of benefit to PPG control due to social, physiological or psychological reasons (It can be administered up to 20 minutes after starting the meal versus Novorapid™ and Humalog™ which are to be administered pre-meal only).
 
Link  APC recommendation: Fiasp insulin (rapid acting insulin aspart) for the management of diabetes mellitus in adults
   
Insulin Lispro 100 units/ml (Humalog®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Soluble insulin - human (Actrapid®, Humulin S®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

Approved for licensed use, and the following off-label indication:

Hyperkalaemia - Use in accordance with locally approved guidelines

 
   
Insulin 500 units in 1mL (Humulin R U-500®)
Unlicensed Drug Unlicensed
Red

Insulins to be prescribed by brand name

Concentrated injection

Restricted use – initiation restricted to named consultants only (Dr David Hopkins, KCH)

Continuation of supply and monitoring remains the responsibility of the hospital

 
   
06.01.01.02  Intermediate- and long-acting insulins
Isophane Insulin - human sequence (Humulin I®, Insulatard®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Insulin Detemir (Levemir®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Insulin Glargine 100 units/ml (Abasaglar®)
View adult BNF View SPC online
Formulary
Amber 2

Insulins to be prescribed by brand name

First line insulin glargine 100 unit/mL product when initiating insulin glargine treatment

Insulin glargine 100 units/mL should be prescribed by brand name

Patients whose clinical condition remains stable on Lantus® should continue on their current treatment.

Blanket switching of patients between different insulin glargine preparations is not supported.

Refer to the SE London APC biosimilar glargine 100 units/mL position statement

 
Link  SE London Area Prescribing Committee biosimilar insulin glargine 100 units/mL position statement
   
Insulin Glargine 100 units/ml (Lantus®)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

Not for initiation in new patients (use Abasaglar 100 units/mL insulin glargine biosimilar).

Insulin glargine 100 units/mL to be prescribed by brand name

Patients whose clinical condition remains stable on Lantus® should continue on their current treatment.

Blanket switching of patients between different insulin glargine preparations is not supported.

Refer to SE London APC insulin glargine 100 units/mL biosimilar position statement.

 
Link  SE London Area Prescribing Committee biosimilar insulin glargine 100 units/mL position statement
   
Insulin Glargine 300 units/ml (Toujeo®)
View adult BNF View SPC online
Restricted Drug Restricted
Amber 2

Insulins to be prescribed by brand name

Specialist initiation only

Restricted to patients already on long acting insulin analogues (e.g. insulin glargine or detemir) who:

  • Experience painful injections with high volumes (>60 units in a single injection) of their current 100 units/ml long acting insulin analogue and/or
  • Suffer from recurrent episodes of nocturnal hypoglycaemia

Not bioequivalent to insulin glargine 100 units/ml dose for dose. Switches to Toujeo® from other insulins require dose adjustment (see SPC and below for further information)

 
Link  SE London APC recommendation: Toujeo for type 2 diabetes in adults
Link  MHRA Apr 2015: High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error
Link  Toujeo: Guide for healthcare professionals
   
Insulin Degludec (Tresiba®)
View adult BNF View SPC online
Restricted Drug Restricted
Amber 3

Insulins to be prescribed by brand name

Specialist initiation only

Monitoring and continuation of care remains the responsibility of the Specialist for the first 3 months, after which care may be transferred to primary care in accordance with the Transfer of Care document

Restricted to use in children >1 year and adults with type 1 diabetes where:

  • Both insulin detemir and insulin glargine have been tried and the patient still has poorly controlled diabetes and
  • The next step would otherwise be an insulin pump and
  • Psychosocial or other factors indicate the need for longer duration insulin to facilitate continued treatment and avoid decompensation due to the mismanagement of insulin and
  • There have been frequent emergency admissions
 
Link  Interim SE London APC Insulin degludec (Tresiba® ) 100 units/ml, 200units/ml FlexTouch® pen or 100units/ml Penfill® cartridge for T1DM – information sheet
Link  SE London APC Recommendation: Insulin Degludec for diabetes
   
Isophane Insulin - highly purified animal (Hypurin® Bovine Isophane)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
06.01.01.02  Biphasic insulins to top
Biphasic Insulin Aspart (NovoMix® 30)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Biphasic Insulin Lispro (Humalog® Mix)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
Biphasic Isophane Insulin (Humulin® M3)
View adult BNF View SPC online
Formulary

Insulins to be prescribed by brand name

 
   
06.01.01.03  Hypodermic equipment
06.01.01.03  Needles
06.01.01.03  Lancets
06.01.02  Antidiabetic drugs
06.01.02.01  Sulphonyureas to top
Glibenclamide tabs
View adult BNF View SPC online
Formulary  
   
Gliclazide tabs
View adult BNF View SPC online
Formulary  
   
Glipizide tabs
View adult BNF View SPC online
Formulary  
   
Tolbutamide tabs
View adult BNF View SPC online
Formulary  
   
06.01.02.02  Biguanides
Metformin tabs, m/r tabs, oral solution
View adult BNF View SPC online
Formulary Prescribing of oral solution should be restricted for patients who are unable to swallow tablets 
   
Metformin tabs
View adult BNF View SPC online
Formulary

Approved off-label indications:

1. Gestational diabetes - use in accordance with the NICE guidance on diabetes in pregnancy

2. Polycystic ovary syndrome - Dose = 500 mg twice or three times daily

 
Link  NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
   
06.01.02.03  Other antidiabetic drugs
06.01.02.03  Alpha glucosidase inhibitors
Acarbose tabs
View adult BNF View SPC online
Formulary  
   
06.01.02.03  GLP-1 mimetics
Dulaglutide injection
View adult BNF View SPC online
Formulary
Amber 3

Follow SE London APC GLP-1 guidance for criteria for use

Initiation by specialist only.

Ongoing supplies can be requested from primary care after the 3 months review using the transfer of care document (links below)

 
Link  SE London APC recommendation: Dulaglutide for Type 2 diabetes
   
Liraglutide injection
View adult BNF View SPC online
Formulary
Amber 3

Follow SE London APC GLP-1 guidance for criteria for use

Initiation by specialist only.

Ongoing supplies can be requested from primary care after the 3 months review using the transfer of care document (links below)

 
   
Semaglutide injection
View adult BNF View SPC online
Formulary
Amber 3

Follow SE London APC GLP-1 guidance for criteria for use

Initiation by specialist only.

Ongoing supplies can be requested from primary care after the 3 months review using the transfer of care document (links below)

 
Link  SE London APC recommendation: Semaglutide (Ozempic™) 0.25mg, 0.5mg and 1mg solution for injection in a pre-filled pen for type 2 diabetes mellitus
   
06.01.02.03  DPP4 inhibitors (gliptins) to top
Linagliptin tabs
View adult BNF View SPC online
Restricted Drug Restricted Reserved for use in patients with severe renal impairment (eGFR <30 mL/min) 
   
Sitagliptin tabs
View adult BNF View SPC online
Formulary  
   
06.01.02.03  SGLT2 inhibitors
Canagliflozin tabs
View adult BNF View SPC online
Formulary
Green
 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dapagliflozin tabs (type 1 diabetes)
View adult BNF View SPC online
Formulary
Red

Approved as per NICE technology appraisal guidance (see link below)

Specialist diabetologist recommendation only

Currently for hospital prescribing only.  Formal ongoing supply arrangements being reviewed by the APC.

 
Link  MHRA Apr 2016: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
Link  NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
   
Dapagliflozin tabs (type 2 diabetes)
View adult BNF View SPC online
Formulary
Green

Approved as per NICE technology appraisal guidance (see links below)

 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
   
Empagliflozin tabs
View adult BNF View SPC online
Formulary
Green
 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Ertugliflozin tabs
View adult BNF View SPC online
Formulary
Green

 

 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Link  NICE TA583:Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
   
Sotagliflozin tabs (type 1 diabetes)
View adult BNF View SPC online
Formulary
Red

Approved as per NICE technology appraisal guidance (see links below)

 
Link  NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
   
06.01.02.03  Meglitinides
Repaglinide tabs
View adult BNF View SPC online
Formulary  
   
06.01.02.03  SGL2 inhibitors
06.01.02.03  Other
06.01.02.03  Thiazolidinediones to top
Pioglitazone tabs
View adult BNF View SPC online
Formulary  
Link  MHRA Advice - Insulin combined with pioglitazone: risk of cardiac failure, January 2011
Link  MHRA Advice - Pioglitazone: risk of bladder cancer, August 2011
   
06.01.02.07  Other antidiabetic drugs
06.01.03  Diabetic ketoacidosis
06.01.04  Treatment of hypoglycaemia
Glucagon injection (GlucaGen® HypoKit)
View adult BNF View SPC online
Formulary  
   
Glucose oral gel 40%
View adult BNF View SPC online
Formulary  
   
06.01.04  Chronic hypoglycaemia
Diazoxide tabs
View adult BNF View SPC online
Formulary
Red
 
   
06.01.05  Treatment of diabetic nephropathy and neuropathy to top
06.01.06  Diagnostic and monitoring agents for diabetes mellitus
Flash glucose monitoring (Freestyle libre®)
Formulary
Amber 3

Approved for use in the patient groups as listed in the Area Prescribing Committee Position Statement (link below)

 
Link  APC Position Statement: Flash Glucose Monitoring systems
Link  Flash Glucose initiation letter
Link  Flash Glucose Monitoring in South East London - Guidance and Pathway
Link  Flash Glucose patient prescriber agreement and transfer of prescribing
Link  Flash Glucose 6-9 month review letter
Link  Flash Glucose Community Pharmacy Information Sheet
Link  Flash Glucose Competencies and Resources
Link  Flash Glucose Patient FAQ
Link  Flash Glucose Primary Care information Sheet
Link  South East London Flash Glucose - safe disposal arrangements
   
06.01.06  Blood glucose monitoring
Advantage II®
View adult BNF View SPC online
Formulary NOT TO BE USED BY PATIENTS UNDERGOING CAPD 
   
BM-Accutest®
View adult BNF View SPC online
Formulary Glucose monitoring 
   
Glucostix®
View adult BNF View SPC online
Formulary  
   
MediSense® Optium H
View adult BNF View SPC online
Formulary For blood glucose monitoring on wards and outpatient departments 
   
Multistix 8 SG®
View adult BNF View SPC online
Formulary  
   
StatStrip®
View adult BNF View SPC online
Formulary For blood glucose and ketone monitoring within GSTFT 
   
06.01.06  Urinalysis
Albustix®
View adult BNF View SPC online
Formulary

Protein detection

 
   
Combur Test® 7
View adult BNF View SPC online
Formulary Blood, leucocytes, nitrate, glucose, protein, ketone and pH detection 
   
Diastix®
View adult BNF View SPC online
Formulary Glucose detection 
   
Ketostix®
View adult BNF View SPC online
Formulary Ketones detection 
   
Uristix®
View adult BNF View SPC online
Formulary Glucose and protein detection 
   
06.01.06  Blood glucose meters for adults with type 2 diabetes
06.01.06  Blood glucose meters for children and adults with type 1 diabetes to top
06.01.06  Blood glucose meters for patients on continuous insulin infusion pump
06.01.06  Blood glucose meters for patients with dexterity problems
06.01.06  Talking blood glucose meters
06.02  Thyroid and Antithyroid drugs
06.02.01  Thyroid hormones to top
Levothyroxine tabs, oral solution
View adult BNF View SPC online
Formulary  
   
Liothyronine injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved for licensed use, and off-label for rapid control of hypothyroidism in patients with impairment of absorption or in patients with a medical history precluding administration of oral medications

 
   
Liothyronine tabs (resistant depression - off-label)
View adult BNF View SPC online
Formulary
Red

Approved for:

Monotherapy or combination therapy for the treatment of resistant depression

Consultant psychiatrist initiation only where no other options have worked.

See APC Position Statement (link below) for further details.

 
Link  SE London APC Position Statement: Liothyronine monotherapy or combination therapy for the treatment of resistant depression
   
Liothyronine tabs (thyroid replacement prior to radioiodine)
View adult BNF View SPC online
Formulary
Red

Approved for:

Temporary thyroid replacement therapy after thyroidectomy and prior to radioiodine therapy.

Hospital only prescribing

See APC Position Statement (link below) for further details.

 
Link  SE London APC Recommendation: Liothyronine tablets for temporary thyroid replacement therapy after thyroidectomy and prior to radioiodine therapy
   
06.02.02  Antithyroid drugs
Aqueous Iodine oral solution (Lugol's)
View adult BNF View SPC online
Formulary  
   
Carbimazole tabs
View adult BNF View SPC online
Formulary Refer to BNF for CSM advice on neutropenia and agranulocytosis 
Link  MHRA Feb 19: Carbimazole: increased risk of congenital malformations; strengthened advice on contraception
Link  MHRA Feb 19: Carbimazole: risk of acute pancreatitis
   
Propylthiouracil tabs
View adult BNF View SPC online
Formulary  
   
Methylthioninium chloride injection 0.5%, 1%, 2% (methylene blue)
Unlicensed Drug Unlicensed
Red

Diagnostic agent used for staining parathyroid glands.

Maximal staining of glands occurs if infused intravenously for 1 hour prior to operation

Dose: 5 mg/kg actual body weight in 250 mL dextrose/saline

 
Link  MHRA Apr 2009: Methylthioninium chloride (methylene blue): update on central nervous system (CNS) toxicity with serotonergic antidepressants
   
Methylthioninium chloride injection 2% (methylene blue)
Unlicensed Drug Unlicensed
Red

For testing intragastric balloon insertions and as a dye for patients with polyps undergoing colonoscopies (Endoscopy/Day Surgery)

For checking bladder patency secondary to injury during C-sections and checking fallopian tube patency (Birth Centre Theatres)

 
Link  MHRA Apr 2009: Methylthioninium chloride (methylene blue): update on central nervous system (CNS) toxicity with serotonergic antidepressants
   
Potassium Iodate tabs
Unlicensed Drug Unlicensed

Protection of thyroid function during radioactive iodine therapy

Dose: 130 mg daily

 
   
06.03  Corticosteroids
06.03.01  Replacement therapy
Fludrocortisone tabs
View adult BNF View SPC online
Formulary

Approved for licensed indication(s) and for the treatment of Postural Orthostatic Tachycardia Syndrome (POTS)/Inappropriate Sinus Tachycardia (IST) - see information regarding fludrocortisone within the SE London APC recommendation for midodrine in POTS/IST (link below). 


 
Link  SE London APC Recommendation: Midodrine for the treatment of Postural Orthostatic Tachycardia Syndrome (POTS)/Inappropriate Sinus Tachycardia (IST)
   
Fludrocortisone tabs (diagnostic test for incomplete distal renal tubular acidosis)
View adult BNF View SPC online
Formulary
Red

Approved off-label use

Dose = simultaneous oral administration of fludrocortisone 1 mg and furosemide 40 mg 


 
   
06.03.02  Glucocorticoid therapy
Betamethasone soluble tabs, injection
View adult BNF View SPC online
Formulary  
   
Betamethasone tabs
View adult BNF View SPC online
Formulary  
   
Cortisone tabs
View adult BNF View SPC online
Formulary  
   
Dexamethasone injection (palliative care)
View adult BNF View SPC online
Formulary
Amber 1

GPs may be asked to prescribe dexamethasone injections as part of palliative care in the community setting

Palliative care recommendation only

 
   
Dexamethasone tabs, soluble tabs, oral solution, injection
View adult BNF View SPC online
Formulary

 
   
Hydrocortisone MR tabs (Plenadren®)
View adult BNF View SPC online
Formulary
Red

Consultant specialists only

Restricted to patients with primary adrenal insufficiency (AI) who have experienced at least two hospital admissions in the last 12 months due to unstable AI.

Use in secondary AI is not currently recommended

 
Link  SE London APC recommendation: Plenadren for primary adrenal insufficiency in adults
   
Hydrocortisone sodium succinate injection (Solu-Cortef)
View adult BNF View SPC online
Formulary

 
   
Hydrocortisone sodium succinate injection (Solu-Cortef or PanPharma brand - off-label intrathecal use in haemato-oncology)
View adult BNF View SPC online
Formulary
Red

Approved off-label use:

  • Intrathecal use in haemato-oncology chemotherapy regimens
  • Solu-Cortef or PanPharma brands must be used
  • Internal Trust guidance and protocols should be strictly followed
 
   
Hydrocortisone tabs
View adult BNF View SPC online
Formulary

 
   
Methylprednisolone acetate depot injection (Depo-Medrone®)
View adult BNF View SPC online
Formulary  
   
Methylprednisolone sodium succinate injection (Solu-Medrone®)
View adult BNF View SPC online
Formulary  
Link  MHRA Oct 17: Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows’ milk allergy
   
Methylprednisolone tabs
View adult BNF View SPC online
Formulary  
   
Prednisolone tabs, soluble tabs
View adult BNF View SPC online
Formulary Prednisolone enteric coated tablets are non-formulary 
   
Triamcinolone acetonide injection (Kenalog® - asthma)
View adult BNF View SPC online
Restricted Drug Restricted
Red

Specialist asthma clinic at GSTFT only

For treatment of severe asthma

Restricted to use in patients requiring continuous use of oral steroids where response to oral treatment has been insufficient

 
   
Methylprednisolone sodium succinate injection (Solu-Medrone® - intratympanic use [off-label])
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Intratympanic injection for sudden sensorineural hearing loss or Meniere’s disease

Dose = 40mg, with a maximum of 3 injections 1 week apart

Consultant ENT specialist use only

 
   
Dexamethasone tabs, soluble tabs, oral solution, injection (COVID-19)
View adult BNF View SPC online
Formulary
Red

Approved for:

Treatment of confirmed or suspected COVID-19 in patients having oxygen therapy, non-invasive or invasive ventilation or ECMO

  • Dose (all preparations) = 6 mg daily for 10 days (treatment should stop if discharged within the 10 days)
  • Prednisolone or hydrocortisone (IV) should be used in pregnancy (see separate monographs)
  • See MHRA alert for more information
 
   
Hydrocortisone sodium succinate injection (COVID-19)
View adult BNF View SPC online
Formulary
Red

Approved for:

Treatment of suspected or confirmed COVID-19 in pregnant patients having oxygen therapy, non-invasive or invasive ventilation or ECMO

  • Dose: 80 mg twice a day for 10 days (treatment should be stop if discharged within the 10 days).
  • Dexamethasone should be used in non-pregnant patients (see separate formulary entry)
  • See MHRA alert for more information
 
   
Prednisolone tabs, soluble tabs (COVID-19)
View adult BNF View SPC online
Formulary
Red

Approved for:

Treatment of suspected or confirmed COVID-19 in pregnant patients having oxygen therapy, non-invasive or invasive ventilation or ECMO.

  • Dose: 40 mg daily for 10 days (treatment should be stop if discharged within the 10 days)
  • Dexamethasone should be used in non-pregnant patients (see separate formulary entry)
  • See MHRA alert for more information
 
   
Prasterone caps (DHEA)
Unlicensed Drug Unlicensed Treatment of adrenal insufficiency Dose: 25-50 mg daily 
   
06.04  Sex hormones to top
06.04.01  Female sex hormones and their modulators
06.04.01.01  Oestrogens and HRT
Cyclo-Progynova® tabs (estradiol valerate and norgestrel)
View adult BNF View SPC online
Formulary  
   
Duavive® MR tabs (Conjugated oestrogens and bazedoxifene)
View adult BNF View SPC online
Restricted Drug Restricted
Amber 2

Secondary care initiation only

Restricted to use (as per product licence) where progestin containing therapy is not appropriate

 
Link  APC recommendation: Duavive for oestrogen deficiency in the menopause
   
Estraderm ® patches (estradiol)
View adult BNF View SPC online
Formulary  
   
Estradiol 0.06% gel (Oestrogel)
View adult BNF View SPC online
Formulary
Green

For oestrogen deficiency symptoms in postmenopausal women who have experienced adverse reactions to HRT patches, e.g. skin irritation

First choice topical oestrogen gel for HRT

See APC recommendation for further information 

 
Link  APC recommendation: Estradiol gels - for oestrogen deficiency symptoms in postmenopausal women
   
Estradiol 0.5mg gel (Sandrena®)
View adult BNF View SPC online
Formulary
Green

For oestrogen deficiency symptoms in postmenopausal women who have experienced adverse reactions to HRT patches, e.g. skin irritation

Second choice topical oestrogen gel for HRT

See APC recommendation for further information

 
Link  APC recommendation: Estradiol gels - for oestrogen deficiency symptoms in postmenopausal women
   
Estradiol tabs
View adult BNF View SPC online
Formulary  
   
Evorel® Conti patches (estradiol and norethisterone)
View adult BNF View SPC online
Formulary  
   
Evorel® patches (estradiol)
View adult BNF View SPC online
Formulary  
   
Evorel® Sequi patches
View adult BNF View SPC online
Formulary Combination of estradiol only and estradiol and progesterone patches (sequential use) 
   
Femoston® tabs (estradiol with dydrogesterone)
View adult BNF View SPC online
Formulary  
   
FemSeven® patches (estradiol)
View adult BNF View SPC online
Formulary  
   
Hormonin® tabs (estradiol)
View adult BNF View SPC online
Formulary  
   
Kliofem® tabs (estradiol and norethisterone)
View adult BNF View SPC online
Formulary  
   
Kliovance® tabs (estradiol and norethisterone)
View adult BNF View SPC online
Formulary  
   
Premarin® tabs (conjugated oestrogens)
View adult BNF View SPC online
Formulary  
   
Tibolone tabs
View adult BNF View SPC online
Formulary  
   
Trisequens® tabs (estradiol and norethisterone)
View adult BNF View SPC online
Formulary  
   
Femoston Conti® tabs (estradiol with dydrogesterone)
View adult BNF View SPC online
Formulary  
   
Estradiol implants 25mg and 50mg
View adult BNF View SPC online
Unlicensed Drug Unlicensed

Approved for use in:

  • HRT for estrogen deficiency symptoms in postmenopausal women
  • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

Dose: 25-100 mg subcutaneously, every 4-8 months

 
   
06.04.01.01  Ethinylestradiol
Ethinylestradiol tabs
View adult BNF View SPC online
Formulary  
   
06.04.01.01  Raloxifene
Raloxifene tabs
View adult BNF View SPC online
Formulary  
Link  NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Link  NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
   
06.04.01.01  Oestrogen only tablets to top
06.04.01.01  Oestrogens and progestogen sequential combined therapy
06.04.01.01  Continuous combined therapy
06.04.01.01  Gonadomimetic
06.04.01.01  Selective oestrogen modulator
06.04.01.02  Progestogens to top
Medroxyprogesterone acetate tabs
View adult BNF View SPC online
Formulary  
   
Norethisterone tabs
View adult BNF View SPC online
Formulary  
   
Progesterone (micronised) oral caps (Utrogestan®)
View adult BNF View SPC online
Formulary

 
   
Progesterone pessaries (Cyclogest®)
View adult BNF View SPC online
Formulary  
   
Ulipristal 5mg tabs (Esmya ® - currently unavailable)
View adult BNF View SPC online
Formulary
Red

Unavailable whilst the European Medicines Agency reviews possible link between Esmya (ulipristal acetate) 5mg tablets and serious liver injury  

  • All patients currently being treated with Esmya (ulipristal acetate) 5mg tabs for uterine fibroids should stop taking their medication and be reviewed for other possible treatments for uterine fibroids.
  • Healthcare professionals should stop prescribing Esmya for treatment of uterine fibroids. No new patients should start treatment with the medicines, which has been suspended throughout the EU during the review. Consider other treatment options as appropriate. 
  • Liver function testing should be performed 2- 4 weeks after treatment has stopped (see SPC for further information)
  • Patients should look out for any signs and symptoms of liver injury (such as nausea, vomiting, right hypochondrial pain, anorexia, asthenia, jaundice) which could occur after stopping treatment.

Link to the full MHRA Alert can be found here

SEL APC temporary withdrawal notices of previous formulary recommendations can be found below

 
Link  MHRA March 20 - Ulipristal acetate 5mg tabs (Esmya) for treatment of uterine fibroids: currently unavailable due to ongoing safety concerns of serious liver injury
Link  Temporary withdrawal of formulary recommendation number 021: Ulipristal for the pre-operative treatment of moderate to severe symptoms of uterine fibroids
Link  Temporary withdrawal of formulary recommendation number 056: Ulipristal for the intermittent treatment of moderate to severe uterine fibroids in women of reproductive age
   
Progesterone pessaries (Cyclogest®)
View adult BNF View SPC online
Formulary

Approved off-label indication:

Assisted conception Dose: 400 mg twice daily

 
   
06.04.02  Male sex hormones and antagonists
Testosterone gel  (Tostran®, Testogel®)
View adult BNF View SPC online
Formulary
Amber 1

Intitiation by specialist only

Male hypogonadism due to androgen deficiency (confirmed by clinical features and biochemical tests)

 
   
Testosterone gel  (Tostran®, Testogel® - off-label menopausal women)
View adult BNF View SPC online
Formulary
Amber 2

Approved off-label indication: For use in women with decreased libido in the menopause

See SEL APC recommendation for more detailed information including dosage (link below) as well as supporting patient information leaflet 

 
Link  Patient information leaflet: Testosterone gel or sachets for the treatment of low sex drive in the menopause
Link  SE London APC Recommendation: Testosterone in topical gel formulation for use in women with decreased libido in the menopause (Tostran™ 2% gel and Testogel™ 50mg in 5 grams)
   
Testosterone salts injection (Sustanon 250®)
View adult BNF View SPC online
Formulary
Amber 1

 
   
Testosterone undecanoate caps (Restandol Testocaps®)
View adult BNF View SPC online
Formulary
Amber 1
 
   
Testosterone undecanoate injection (Nebido®)
View adult BNF View SPC online
Formulary
Amber 1
 
   
Testosterone implant
View adult BNF
Unlicensed Drug Unlicensed
Red
Imported product - not licensed in the UK 
   
06.04.02  Anti-androgens
Cyproterone acetate tabs
View adult BNF View SPC online
Formulary
Amber 2
 
Link  MHRA Alert June 20: new advice to minimise risk of meningioma
   
Finasteride tabs
View adult BNF View SPC online
Formulary  
Link  NICE CG97: Lower urinary tract symptoms
   
06.04.03  Anabolic steroids
Nandrolone injection
View adult BNF View SPC online
Formulary  
   
06.04.04  Gender dysphoria
06.05  Hypothalamic and pituitary hormones and anti-oestrogens to top
06.05.01  Hypothalamic and anterior pituitary hormones and anti-oestrogens
06.05.01  Anti-oestrogens
Clomifene tabs (fertility treatment in Klinefelter syndrome - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Fertility treatment in Klinefelter syndrome

  • Usual trial length = 6 months
  • Dose = 50 mg on alternate days
 
   
Clomifene tabs (licensed use)
View adult BNF View SPC online
Formulary
Amber 2

 
   
06.05.01  Anterior pituitary hormones
Chorionic gonadotrophin injection (licensed use)
View adult BNF View SPC online
Formulary
Red

 
   
Follitropin alfa injection
View adult BNF View SPC online
Formulary
Red

Biosimilar products available, to be prescribed by brand name.

Contact pharmacy department for advice on brand for routine prescribing if unsure

Note: 1st choice product at KCH is the Ovaleap brand ®

 
   
Follitropin beta injection
View adult BNF View SPC online
Formulary
Red
 
   
Human menopausal gonadotrophins (menotrophin - licensed use)
View adult BNF View SPC online
Formulary
Red

 
   
Pegvisomant injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Use under specialist supervision only

Third line, as per criteria in NHSE policy 16050/P

 
Link  NHSE 16050/P: Pegvisomant for acromegaly as a third - line treatment (adults)
   
Somatropin injection
View adult BNF View SPC online
Formulary
Amber 3
High Cost Medicine

Initiation by specialist only

 
Link  NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Link  NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Link  SE London APC Shared Care Agreement: Somatropin in paediatrics
   
Tetracosactide injection, depot injection
View adult BNF View SPC online
Formulary
Red
 
   
Thyrotropin alfa injection
View adult BNF View SPC online
Formulary
Red
 
   
Chorionic gonadotrophin injection (fertility treatment in Klinefelter syndrome - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Fertility treatment in Klinefelter syndrome

  • Usually added to regimen after clomifene tablets
  • Usual trial length = 6 months
  • Dose = 2,000 units three times a week
 
   
Human menopausal gonadotrophins (menotrophin - fertility treatment in Klinefelter syndrome - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Fertility treatment in Klinefelter syndrome

  • Usually added to regimen after clomifene tablets and HCG injections
  • Usual trial length = 6 months
  • Dose = 75 units twice a week
 
   
Arginine injection
Unlicensed Drug Unlicensed Assessment of growth disorders; hyperammonaemia; metabolic alkalosis 
   
Corticotropin (corticotrophin) releasing hormone injection
Unlicensed Drug Unlicensed

Test for adrenal insufficiency

 
   
06.05.01  Hypothalmic hormones
Gonadorelin injection
View adult BNF View SPC online
Formulary
Red
 
   
Protirelin injection
View adult BNF View SPC online
Formulary
Red
 
   
Sermorelin injection
View adult BNF View SPC online
Formulary
Red
 
   
06.05.02  Posterior pituitary hormones and antagonists to top
06.05.02  Posterior pituitary hormones
Desmopressin nasal spray (licensed use)
View adult BNF View SPC online
Formulary

To be used as per licensed indications only (see SPC)

Following MHRA safety advice, desmopressin nasal spray must not be prescribed for primary nocturnal enuresis

 

 
Link  MHRA Sept 2007: Desmopressin nasal spray: removal of nocturnal enuresis indication
   
Desmopressin injection (kidney biopsy -off-label)
View adult BNF View SPC online
Formulary
Red

Approved for all licensed indications and the following off-label indication:

Administered before a kidney biopsy to reduce the risk of bleeding

 
   
Terlipressin injection
View adult BNF View SPC online
Formulary
Red
 
   
Terlipressin injection
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Hepatorenal syndrome

For initiation on specialist advice only

 
   
Vasopressin injection (argipressin)
View adult BNF View SPC online
Formulary
Red
 
   
Vasopressin injection (argipressin)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

For use as a vasopressor

Dose = 0.6 to 2.4 units per hour

For initiation on consultant advice only Use in accordance with critical care guideline at GSTFT

 
   
06.05.02  Antidiuretic hormone antagonists
Tolvaptan tabs (Jinarc® - polycystic kidney disease)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
For autosomal dominant polycystic kidney disease as per NICE TA358 
Link  NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease
   
Tolvaptan tabs (Samsca® - SIADH in cancer chemotherapy patients)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
For SIADH in cancer patients requiring chemotherapy as per criteria in NHSE 16051/P 
Link  NHSE 16051/P: Tolvaptan for SIADH in patients requiring cancer chemotherapy
   
Tolvaptan tabs (Samsca® - SIADH in non-cancer patients)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
Treatment of non-cancer related SIADH, with the following restrictions:
  • Initiation under the advice of endocrinology only
  • Ongoing clinical review from endocrinology
  • Patients with plasma sodium < 130mmol/L
  • Maximum treatment duration should be no more than 28 days
  • All supplies from the hospital only 
  •    
    Demeclocycline caps
    View adult BNF
    Unlicensed Drug Unlicensed  
       
    06.06  Drugs affecting bone metabolism
    06.06.01  Calcitonin and parathyroid hormone
    Calcitonin (salmon) / Salcatonin nasal spray, injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Teriparatide injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
     
    Link  NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
       
    Teriparatide injection
    View adult BNF View SPC online
    Formulary
    Red

    Approved for treating osteoporosis in men (adults) as per NHSE policy criteria (see link below)

     
    Link  Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) (170064P)
       
    06.06.02  Bisphosphonates and other drugs affecting bone metabolism to top
     note  For pain relief in men with hormone-refractory prostate cancer, refer to NICE clinical guideline 175
    06.06.02  Bisphosphonates
    Alendronic acid tabs
    View adult BNF View SPC online
    First Choice FIRST-LINE ORAL BISPHOSPHONATE 
    Disodium etidronate tabs
    View adult BNF View SPC online
    Formulary  
       
    Disodium pamidronate injection
    View adult BNF View SPC online
    Formulary
    Red

    Approved for licensed use, and the following off-label indication:

    Non-malignant hypercalcaemia - follow local guidelines

     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Ibandronic acid injection
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    CONSULTANT SPECIALISTS ONLY

    Treatment of osteoporosis in postmenopausal women at increased risk of fracture, who do not tolerate oral bisphosphonates

     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Risedronate tabs
    View adult BNF View SPC online
    Formulary  
       
    Risedronate, calcium carbonate and colecalciferol tabs
    View adult BNF View SPC online
    Formulary  
       
    Sodium clodronate caps, tabs
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Zoledronic acid injection 4mg (licensed use)
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    RESTICTED USE – ONCOLOGY, HAEMATOLOGY & UROLOGY ONLY

     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Zoledronic acid injection 5mg
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    CONSULTANT SPECIALISTS ONLY

    • Paget’s disease of the bone
    • Osteoporosis in post-menopausal women and men at increased risk of fracture
    • Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture
    • Prevention of osteoporosis associated with long-term high dose systemic glucocorticoid therapy, where oral bisphosphonates are not possible (off-label)
     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Zoledronic acid injection 4mg (Improved outcomes in early stage post-menopausal breast cancer - off-label)
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Approved off-label indication:

    Improved outcomes in early stage post-menopausal breast cancer

    Dose = 4mg infusion every 6 months after completion of adjuvant chemotherapy - maximum 5 years treatment

    Consultant oncologists only

     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    06.06.02  Denosumab
    Denosumab (Prolia®)
    View adult BNF View SPC online
    Formulary
    Red

    Approved for:

    Secondary prevention of osteoporotic fragility fractures in male patients with osteoporosis and a creatinine clearance <30mL/min

    Consultant Specialists only - use in accordance with local guideline

    Hospital prescribing only

     
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Denosumab (Prolia®)
    View adult BNF View SPC online
    Formulary
    Amber 3

    Approved as per NICE Technology Appraisal 204 (prevention of osteoporotic fractures in postmenopausal women):

    Consultant specialist initiation only - use in accordance with local guideline

    GPs may be asked to continue the prescribing in post-menopausal women with a ceatinine clearance > 35mL/min under the local shared care agreement in Lambeth and Southwark

     
    Link  NICE TA204: Osteoporotic fractures - denosumab
    Link  SE London Arae prescribing Committee: Interim arrangement for prescribing and administration of Denosumab (Prolia®) in primary care for the prevention of osteoporotic fractures during the COVID-19 pandemic
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    Denosumab (XGEVA®)
    View adult BNF View SPC online
    Formulary
    Red

    Approved as per NICE technology appraisal guidance (links below)

     
    Link  MHRA Jun 2018: Denosumab (Xgeva▼) for advanced malignancies involving bone - study data show new primary malignancies reported more frequently compared to zoledronate
    Link  MHRA Jun 2018: Denosumab (Xgeva▼) for giant cell tumour of bone - risk of clinically significant hypercalcaemia following discontinuation
    Link  NICE TA265: Bone metastases from solid tumours - denosumab
    Link  MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
       
    06.06.02  Strontium renelate
    06.07  Other endocrine drugs
    06.07.01  Bromocriptine and other dopaminergic drugs to top
    Bromocriptine tabs
    View adult BNF View SPC online
    Formulary  
       
    Cabergoline tabs (licensed use, and use in breast pain)
    View adult BNF View SPC online
    Formulary
    Amber 2

    Licensed for the following indications:

    • Inhibition or suppression of physiological lactation after delivery
    • Treatment of hyperprolactinaemic disorders

    Approved for following off-label indication:

    • Breast pain
    • Dose = 500 micrograms weekly, or as divided doses on separate days, increased if necessary

    USE ON SPECIALIST ADVICE

     
       
    06.07.02  Drugs affecting gonadotrophins
    Cetrorelix injection
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    INITIATION BY CONSULTANT SPECIALIST ONLY

    For the prevention of irreversible premature ovarian failure in women of child bearing age who are at risk due to the use of cyclophosphamide in the treatment of systemic lupus erythematosus, systemic vasculitis and anti-GBM disease

    Use in accordance with local guideline at KCH

     
       
    Danazol caps (anaemia in myelofibrosis off-label indication)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off label indication:

    Management of anaemia in myelofibrosis 

    Dose = 200-800mg per day 

     
       
    06.07.02  Gonadorelin analogues
    Buserelin injection, nasal spray (Suprecur® - gynaecology)
    View adult BNF View SPC online
    Formulary
    Red
    Pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins 
       
    Goserelin implant (gynaecology indications)
    View adult BNF View SPC online
    Formulary
    Amber 1

    Initiation on recommendation of consultant specialist only

     

     
       
    Leuprorelin acetate pro-longed release injection (gynaecology indications)
    View adult BNF View SPC online
    Formulary
    Amber 1

    Initiation on recommendation of consultant specialist only

     

     
       
    Nafarelin nasal spray
    View adult BNF View SPC online
    Formulary
    Red
    Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation 
       
    Triptorelin SR injection (gynaecology indications)
    View adult BNF View SPC online
    Formulary
    Amber 1

    Initiation on recommendation of consultant specialist only

     

     
       
    06.07.02  Breast pain (mastalgia)
    06.07.03  Metyrapone
    Metyrapone caps
    View adult BNF View SPC online
    Formulary
    Red
    SPECIALIST SUPERVISION ONLY 
       
    06.07.04  Somatomedins to top
     ....
     Non Formulary Items
    Dutasteride  (Avodart®)

    View adult BNF View SPC online
    Non Formulary
    Grey
     
    Dutasteride & tamsulosin  (Combodart®)

    View adult BNF View SPC online
    Non Formulary
    Grey
    Link  SE London APC recommendation: Combodart for benign prostatic hyperplasia (not approved)
     
    Exenatide injection, prolonged release injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    No longer approved for initiation in new patients in SE London.

     
    Ibandronic acid tabs

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London (all indications)

     
    Liothyronine tabs  (hypothyroidism)

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London (either as monotherapy, or as combination therapy with levothyroxine) - See APC Position Statement (link below)

    Link  SE London APC position statement: Prescribing of liothyronine tablets (monotherapy or in combination with levothyroxine) for hypothyroidism (not recommended)
     
    Lixisenatide injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    No longer approved for initiation in new patients in SE London.

     
    Unlicensed thyroid extracts

    Non Formulary
    Grey

    Including: Armour thyroid, ERFA Thyroid, Nature-Thyroid

    Not approved for use in SE London - See APC Position Statement (link below)

    Link  SE London APC Position Statement: Unlicensed thyroid extracts (not recommended for prescribing)
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary